2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2129

Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI
Abstract Number: 2130

Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Low-Dose Aspirin: A Case-Crossover Study
Abstract Number: 2131

Younger Age and Female Gender Are the Main Determinants of Underestimation of Cardiovascular Risk in Rheumatoid Arthritis Patients
Abstract Number: 2132

Monocarboxylate Transporter 4, Associated with the Acidification of Synovial Fluid, Is a Novel Therapeutic Target for Inflammatory Arthritis
Abstract Number: 2133

Receptor Protein Tyrosine Phosphatase Alpha Enhances Rheumatoid Synovial Fibroblast Signaling and Promotes Arthritis in Mice
Abstract Number: 2134

Metabolic Reprogramming in the Inflamed Joint Inhibits Pro-Inflammatory Mechanisms
Abstract Number: 2135

miRNA-223 Delivery to Synovial Fibroblasts Via Monocyte-Derived Extracellular Vesicles Promotes Their Proliferation
Abstract Number: 2136

Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis
Abstract Number: 2137

Critical Role of Fibroblast-like Synoviocytes Glycolytic Metabolism in Rheumatoid Arthritis
Abstract Number: 2138

Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Abstract Number: 2139

Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2140

Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract Number: 2141

Risk of Cancer in Non-TNFi Biologics-Treated RA
Abstract Number: 2142

Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Abstract Number: 2143

A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].